Table 1 Clinical and epidemiological characteristics of HIV/HCV-coinfected patients
Characteristics | All patients |
|---|---|
No. (%) | 220 (100%) |
Male, n (%) | 162 (73.6%) |
Age, years | 39.8 (37.4; 44) |
HIV acquired by IDU, n (%) | 193 (87.7%) |
Years since HCV infection | 21.3 (17.1; 24.4) |
Prior AIDS, n (%) | 60 (27.3%) |
cART, n (%) | 183 (83.2%) |
Time on cART, years | 4.4 (2.5; 6.7) |
Current cART protocols, n (%) | |
PI-based | 50 (22.7%) |
NNRTI-based | 114 (51.8%) |
NRTI-based | 129 (58.6%) |
Metabolic markers | |
BMI, kg/m2 | 22.4 (20.8; 24.6) |
BMI ≥25 kg/m2 | 50 (22.9%) |
HOMA | 2.10 (1.27; 3.73) |
HOMA ≥3 | 71 (33.5%) |
HIV markers | |
Nadir CD4+, T cells/μL | 192 (84; 318) |
CD4+, T cells/μL | 467 (324; 672) |
HIV-RNA <50 copies/mL, n (%) | 162 (73.6%) |
HCV markers, n (%) | |
HCV-RNA ≥500.000 IU/ml | 162 (74.7%) |
HCV genotype | 216 (98.2%) |
HCV-GT1 | 123 (55.9%) |
HCV-GT2 | 5 (2.3%) |
HCV-GT3 | 50 (22.7%) |
HCV-GT4 | 38 (17.3%) |
Metavir score, n (%) | |
Significant fibrosis (F ≥ 2) | 109 (49.5%) |
Advanced fibrosis (F ≥ 3) | 49 (23.3%) |
Cirrhosis (F4) | 23 (10.5%) |
Moderate activity grade (A ≥ 2) | 114 (52.8%) |
Severe activity grade (A3) | 24 (11.1%) |
Fibrosis indexes | |
APRI | 0.75 (0.45; 1.30) |
APRI ≥1.5 | 36 (17.2%) |
FIB-4 | 1.43 (1.03; 2.03) |
FIB-4 ≥3.25 | 20 (9.6%) |